November 11, 2026 · Gynecologic oncology · DOI: 10.1016/j.ygyno.2026.10.026

BEHOLD phase 3 clinical development program of mocertatug rezetecan in ovarian and endometrial cancer.

Listen to this summary

This paper describes the design of the BEHOLD Phase 3 program, which tests mocertatug rezetecan (Mo-Rez), a B7-H4-targeting antibody-drug conjugate, across five randomized studies in ovarian and endometrial cancer involving about 3,070 patients. The authors aim to determine whether Mo-Rez, which showed promising Phase 1 response rates (62% in platinum-resistant ovarian cancer and 67% in endometrial cancer), improves PFS and/or OS compared with standard care across treatment settings including replacement of chemotherapy, combinations with bevacizumab or immune checkpoint inhibitors, and maintenance therapy. The program also uses prospective tumor collection to assess whether B7-H4 expression and other biomarkers predict clinical benefit.

Jean Hurteau, Michele Grayeski, Joanne Dixon

This is one of 33,000+ journals available on OSLR. Try it free for 14 days.

Free 14-day trial. 33,000+ journals. Cancel anytime.

14-day free trial. No commitment.

“

"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."

Dr. Jennifer Thompson

Dr. Jennifer Thompson

Portland, OR

Stay current without falling behind

33,000+ journals. 3-minute audio summaries. Free for 14 days.

Download on the App StoreGet it on Google Play